49 results
Page 2 of 3
6-K
EX-4.3
d1kze05b3
8 Sep 20
ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement
7:40am
424B5
lpsidiu jumw
8 Sep 20
Prospectus supplement for primary offering
7:31am
6-K
EX-99.1
ovhire9m8i
4 Jun 20
ObsEva Announces Publication of Data Showing Efficacy of Linzagolix in a Potential New Indication for Treatment of Adenomyosis
6:11am
F-3
EX-4.2
49cmdmms
7 Aug 19
Shelf registration (foreign)
8:24am
F-3
EX-4.1
4q5z3x9
7 Aug 19
Shelf registration (foreign)
8:24am
F-3
sst py60qvnwqindb
7 Aug 19
Shelf registration (foreign)
8:24am
424B5
3582zg
7 Aug 19
Prospectus supplement for primary offering
8:18am
6-K
EX-99.1
crb7 iu5xiu
7 Aug 19
Current report (foreign)
7:21am
6-K
EX-3.1
01zjvf
20 May 19
Current report (foreign)
5:28pm
6-K
v119sa
28 Sep 18
Current report (foreign)
8:40am
424B5
0tqul9ktj v6a70nnkr
20 Jun 18
Prospectus supplement for primary offering
5:32pm
424B5
vflvv
18 Jun 18
Prospectus supplement for primary offering
9:15pm
6-K
EX-99.1
tk5vtq3f43aean
18 Jun 18
ObsEva SA Achieves Primary and Secondary Endpoints for EDELWEISS
9:17am
6-K
4jipie 7pkco30t
7 Jun 17
Current report (foreign)
12:00am
20-F
lzwo014
21 Apr 17
Annual report (foreign)
12:00am
F-1
ruitdrlbkb7o
30 Dec 16
Registration statement (foreign)
12:00am